Strategic Clinical Partnerships Leuko already collaborates with MD Anderson Cancer Center and Boston Medical Center, underscoring credibility with major cancer networks and enabling hospital pilots. These references can be leveraged to engage additional top-tier cancer centers and drive procurement discussions, with emphasis on integrating PointCheck into oncology workflows.

At Home Expansion The PointCheck device targets at-home noninvasive white blood cell monitoring for chemotherapy patients, supported by NIH and SBIR funding. This creates opportunities to sell to home health agencies, oncology clinics offering remote monitoring, and durable medical equipment distributors, while pursuing payer conversations for remote monitoring reimbursement.

Funding and Validation External validation from a $4.5M NIH grant and a $5M Series A de-risks adoption and can be used to spark talks with pharma partners for clinical monitoring programs or co-development opportunities.

Market Timing Growing demand for non-invasive WBC testing in chemotherapy management and early infection detection aligns with trends in remote patient monitoring and telehealth. The approach can extend beyond oncology into infectious disease or immune monitoring, broadening the potential addressable market.

Go to Market With a lean team, Leuko should focus on strategic partnerships, hospital procurement routes, GPOs, and telehealth platforms, plus DME and home-health distributors. Develop ROI-focused case studies and pilot programs at cancer centers to accelerate scale.